Endo’s Par Pharmaceutical Recalls Blood Pressure Medication Due to Potential Contamination

1. Endo's subsidiary, Par Pharmaceutical, has issued a recall for a specific lot of its blood pressure medication, quinapril HCl/ hydrochlorothiazide tablets, USP 20 mg/12.5 mg, due to potential contamination.
2. The affected lot number is 0KG190092, with an expiration date of 03/2022.
3. The recall is a precautionary measure to ensure patient safety, as the medication may contain trace amounts of a potential human carcinogen, N-nitroso-quinapril.
4. Patients who have the recalled medication should contact their healthcare provider for advice on alternative treatment options and return the medication to their pharmacy or healthcare provider.
5. Endo and Par Pharmaceutical are working closely with the U.S. Food and Drug Administration (FDA) to manage the recall and minimize any potential impact on patients.
6. The recall is limited to the specific lot number and does not affect other quinapril HCl/ hydrochlorothiazide tablets or any other products manufactured by Endo or Par Pharmaceutical.